The mechanisms controlling expression of the putative oncogene Anterior gradient 2 (AGR2) in pancreatic ductal adenocarcinoma (PDAC) are not well understood. We now show that AGR2 is a transforming growth factor-b (TGF-b)-responsive gene in human pancreatic cancer cells, whose downregulation is SMAD4 dependent. We also provide evidence supporting a role for AGR2 as an ER-chaperone for the cancer-associated mucin, MUC1. AGR2 is both sufficient and required for MUC1 expression in pancreatic cancer cells. Furthermore, AGR2 is coexpressed with MUC1 in mouse pancreatic intraepithelial neoplasia (mPanIN)-like lesions and in the cancer cells of four distinct genetically engineered mouse models of PDAC. We also show that Pdx1-Cre/LSL-Kras G12D / Smad4 lox/lox mice heterozygous for Agr2 exhibit a delay in mPanIN initiation and progression to PDAC. It is proposed that loss of Smad4 may convert TGF-b from a tumor suppressor to a tumor promoter by causing the upregulation of AGR2, which then leads to increased MUC1 expression, at which point both AGR2 and MUC1 facilitate mPanIN initiation and progression to PDAC.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy with a median survival of 6 months and 5-year survival rates of 6%. 1 PDAC is characterized by multiple molecular alterations that include mutations in the K-ras oncogene, and the p53, p16 and SMAD4 tumor suppressor genes occurring in conjunction with overexpression of tyrosine kinase receptors and transforming growth factor-b (TGF-b) isoforms. [2] [3] [4] [5] TGF-bs act as tumor suppressors and inhibit the proliferation of epithelial cell types. 5 However, pancreatic cancer cells are of epithelial origin and are generally resistant to TGF-b-mediated growth inhibition, due to the presence of SMAD4 mutations or deletions, 6 the under-expression of the type I TGF-b receptor 7, 8 and/or the overexpression of inhibitory SMAD6 or SMAD7. 9, 10 Moreover, increased expression of TGF-bs in PDAC is associated with decreased patient survival 11 and, under certain culture conditions, TGF-bs stimulate pancreatic cancer cell growth. 12 Thus, TGF-bs contribute to the biological aggressiveness of PDAC through a variety of mechanisms.
PDAC is also characterized by the presence of an abundant stroma and increased production of mucins. 13 Three mucins in particular have been associated with more rapid disease progression in PDAC: MUC1, MUC4 and MUC5AC. [14] [15] [16] [17] [18] Both MUC1 and MUC4 are directly implicated in cancer progression and metastasis, through their effects on cell-to-cell signaling 19 and as a consequence of their ability to activate EGFR 20, 21 and/or HER2 pathways. 22 Anterior gradient 2 (AGR2) is a secreted protein that contains an endoplasmic reticulum (ER) leader sequence. 23 It is a potential member of the ER-associated protein disulfide isomerase (PDI) family as evidenced by its structural similarity to PDI proteins, [24] [25] [26] and it forms mixed disulfide bonds with the intestinal mucin protein MUC2. 25 AGR2 expression in tumors appears to depend on the tissue of origin, [27] [28] [29] [30] [31] [32] [33] [34] is elevated in a number of adenocarcinomas, 23, 27, [35] [36] [37] [38] and confers a metastatic phenotype when overexpressed in vitro. 27, 39 In PDAC, AGR2 promotes cancer cell dissemination by enhancing the expression of lyosomal proteases, 38 and by increasing cancer cell survival and chemoresistance. 40 In the present study, we sought to further delineate the role of AGR2 in PDAC. We now report that AGR2 is downregulated by TGF-b in a SMAD4-dependent manner and that AGR2 acts as an ER-localized molecular chaperone of MUC1 in pancreatic cancer cells, colocalizes with MUC1 in pancreatic lesions in vivo, and is essential for MUC1 expression. We also show that Pdx1-Cre/LSL-Kras G12D /Smad4 lox/lox mice null for Agr2 exhibit decreased formation of mouse pancreatic intraepithelial neoplasia (mPanIN)-like lesions and attenuated progression to PDAC.
RESULTS
AGR2 expression is regulated by TGF-b AGR2 was identified as a TGF-b1 downregulated gene as part of an effort in our laboratory to discover novel TGF-b-responsive genes in PDAC. 10, 41 To better characterize the interactions between TGF-b1 signaling and AGR2, we studied the effects of TGF-b1 on AGR2 mRNA and protein levels in four human pancreatic cancer cell lines ( Figure 1 ). TGF-b1 markedly decreased AGR2 mRNA levels in COLO-357 and PANC-1 cells, but not in ASPC-1 or BxPC3 cells ( Figure 1a ). TGF-b1-mediated inhibition of AGR2 mRNA levels in PANC-1 and COLO-357 cells was evident as early as 3 h in COLO-357, and was maximal in both cell lines at 24 h ( Figure 1b ). It was preceded by a slight, transient and statistically insignificant increase in AGR2 mRNA levels at 3 h in PANC-1 cells ( Figure 1b ). A luciferase assay was therefore carried out to assess the response of the AGR2 promoter to TGF-b in these cells. It demonstrated that TGF-b1 decreased AGR2 transcriptional activity in PANC-1 cells even at this early time point (Supplementary Figure S1 ), raising the possibility that in these cells TGF-b1 induced a slight early increase in AGR2 mRNA stability.
TGF-b1 also decreased AGR2 protein levels in COLO-357 and PANC-1 cells, but not in ASPC-1 and BxPC3 cells (Figures 1c and d) . A decrease in AGR2 protein could be detected as early as 16 h following TGF-b1 addition in both cell lines and was maximal at 48 h (Figures 1e and f). After confirming antibody specificity (Supplementary Figure S2 ), we determined that this effect was consistent regardless of the concentration of serum used (Supplementary Figure S3 ). AGR2 expression is regulated by SMAD4 ASPC-1 cells harbor a mutated SMAD4, whereas BxPC3 cells are devoid of SMAD4 due to a homozygous deletion of the gene. 6, 42 By contrast, COLO-357 cells and PANC-1 cells express wild-type SMAD4. 43 Inasmuch as SMAD4 is a key effector for canonical TGF-b signaling, 6, 44, 45 we next sought to determine the consequence of restoring wild-type SMAD4 on AGR2 expression. TGF-b1 reduced AGR2 mRNA levels in cells expressing wild-type SMAD4 (COLO-357 and PANC-1), but not in cells with mutated or absent SMAD4 (ASPC-1 and BxPC3; Figures 1 and 2a ). In these cells, however, restoration of SMAD4, irrespective of the absence or presence of TGF-b1, caused a significant decrease in AGR2 mRNA (Figure 2a ).
To determine whether SMAD4 was required for the TGF-b1mediated decrease in AGR2 mRNA levels, COLO-357 cells were stably transfected with the pGIPZ-S4 construct to induce stable SMAD4 knockdown ( Figure 2b ). Suppression of endogenous SMAD4 resulted in increased AGR2 mRNA (not shown) and protein levels ( Figure 2b ), which were no longer modulated by TGF-b1. By contrast, stable transfection of COLO-357 cells with pGIPZ-scr (scrambled control) did not alter endogenous AGR2 protein levels, which were again reduced by TGF-b1 ( Figure 2b ).
Attempts to perform chromatin immunoprecipitation assays to determine whether AGR2 is a transcriptional target of SMAD4 were not successful, likely due to the complicated mechanisms of SMAD4 transcriptional signaling, 46 and the potentially low DNAbinding affinity of SMAD4 in pancreatic cancer cells. Therefore, the 5 0 UTR of AGR2 was screened for established SMAD4-binding CAGA boxes. 45, 47 Previous studies have demonstrated AGR2 responsive reporters using up to À 1.7 kb base pairs of the 5 0 UTR. 30, 48 Two putative SMAD-binding elements (SBEs; underlined sequences) were located within this region: 5 0 -CACAGACAG-3 0 at À 1535 bp and 5 0 -TGCAGACCT-3 0 at À 773 bp. An AGR2 promoter reporter (AGR2-luc) was cloned by placing À 2595 bp of the AGR2 5 0 UTR upstream from the luciferase gene in the pGL3 vector (Supplementary Figure S4a ). Constructs containing a point mutation in one or both of the SBEs in AGR2-luc were also generated.
To confirm that transfection of exogenous SMAD4 (by pCMV5-DPC4-HA 49 ) was sufficient to activate SMAD transcriptional activity, we used the SMAD-responsive luciferase reporter construct SBE4-luc. 50 Figure S4b ). We next determined the effects of SMAD4 expression on AGR2 promoter activity and found that SMAD4 reduced AGR2 promoter luciferase activity twofold ( Figure 2c ). Furthermore, if either or both of the SBEs were mutated, SMAD4 had no effect on AGR2-luc ( Figure 2c ), suggesting that both of these sites are important for SMAD4mediated repression of AGR2.
SBE4-luc was induced threefold in a luciferase assay after expression of SMAD4 alone (Supplementary
AGR2 is localized to the ER of pancreatic cancer cells AGR2 is associated with the ER of intestinal cells. 25, 26 To determine whether AGR2 localized to the ER in pancreatic cancer cells, immunofluorescence (IF) was performed in PANC-1 cells in relation to AGR2 (Figure 3a , red) and the ER-associated chaperone GRP78 (Figure 3a , green). The merged image revealed that they were colocalized, particularly in the peri-nuclear space (Figure 3a ). Moreover, live-cell confocal microscopy on PANC-1 cells expressing AGR2 interacts with and is required for MUC1 expression Mucins are large proteins that require extensive folding in the ER. 51 AGR2 was shown to be essential for the production of intestinal-associated mucin, MUC2. 25 We therefore sought to determine whether AGR2 is also associated with the pancreaticexpressed mucin, MUC1. By IF, AGR2 colocalized with MUC1 in PANC-1 cells, both in the cytoplasm and in the peri-nuclear space (Figure 4a ). Tight colocalization patterns were also observed in COLO-357 and BxPC3 (SMAD4 deficient) cells (Supplementary Figure S5 ). Moreover, co-immunoprecipitation (co-IP) experiments revealed that MUC1, but not MUC4 or MUC5AC, immunoprecipitated with AGR2 ( Figure 4b ).
To determine whether AGR2 was required for MUC1 expression, COLO-357 cells, which express high endogenous levels of AGR2, were transfected to stably express a doxycycline (DOX)-inducible shRNA that targets AGR2 (pTRIPZ-AGR2), or a negative control (pTRIPZ-scramble). After incubation with increasing concentrations of DOX, there was a dose-dependent decrease in both AGR2 mRNA ( Figure 4c ) and protein ( Figure 4d ) levels in the pTRIPZ-AGR2 clones, which was associated with a dose-dependent reduction in MUC1 protein levels (Figure 4d ), but not MUC1 mRNA levels (not shown). In agreement with previous findings, 26 AGR2 silencing in COLO-357 cells created an ER stress response after 48 and 72 h, as evidenced by increased phosphorylation of eIF2a and PERK (Supplementary Figure S6) .
To determine whether the consequences of AGR2 knockdown on MUC1 protein were reversible, we performed a rescue experiment using mouse AGR2 (mAGR2). To first confirm that the pTRIPZ-AGR2 silencing vector did not target mAGR2, cells were transfected with a mAGR2 expression construct (pcDNA-mAGR2), or an empty pcDNA vector. AGR2 and mAGR2 mRNA levels were then measured in sham and mAGR2-transfected populations, either with or without simultaneous activation of the AGR2 silencing vector ( Figure 4e ). As expected, endogenous AGR2 levels were not significantly affected by the transfection of mAGR2, but were diminished about 80% by DOX. Conversely, following pcDNA-mAGR2 transfection, mAGR2 was increased and was not reduced by the silencing vector.
We next determined whether rescuing AGR2 knockdown with mAGR2 would prevent the associated decrease in MUC1 protein levels. AGR2 knockdown was again associated with reduced MUC1 protein levels (Figure 4f ), which was not due to a non-specific effect on MUC genes, as MUC4 levels were not reduced. However, mAGR2 expression prevented AGR2 silencing from altering MUC1 protein levels (Figure 4f ), suggesting that the decrease of MUC1 after AGR2 silencing is specific and reversible. We next sought to determine whether TGF-b1 modulated MUC1 expression. Similar to the pattern of AGR2 inhibition by TGF-b1 ( Figure 1 ), MUC1 levels were decreased, but only in the SMAD4-proficient COLO-357 and PANC-1 cells and not in the BxPC3 cells (ASPC-1 cells did not express MUC1 RNA or protein; Figure 4h ). Of note, MUC1 immunoblots revealed the presence of two bands in PANC-1 cells, suggesting that MUC1 undergoes protein modification or differential folding in these cells.
Inasmuch as AGR2 and MUC1 expression is elevated in PDAC, we next determined if AGR2 overexpression was sufficient to induce MUC1. As AGR2 protein levels were lowest in PANC-1 cells, we created stable PANC-1 clones expressing either an empty pcDNA vector (sham) or a pcDNA-AGR2 expression plasmid. PANC-1 cells that overexpressed AGR2 also had elevated MUC1 levels (Figure 4g ), suggesting that AGR2 expression is sufficient to stabilize MUC1 expression.
AGR2 is associated with MUC1 expression in pancreatic lesions
To determine whether AGR2 and MUC1 were associated in pancreatic lesions in vivo, MUC1 and AGR2 expression was examined by IF in four genetically engineered mouse models (GEMMs) of PDAC: Pdx1-Cre/Kras G12D , 52 Pdx1-Cre/Kras G12D /p53 À / À , 53 Pdx1-Cre/ Kras G12D /Smad4 À / À , 54 and Pdx1-Cre/Kras G12D /Rb À / À . 55 AGR2 was abundant in all mPanIN-like stages, including mPanIN-1A, and in the cancer cells in PDAC (Supplementary Figure S7 ). MUC1 was also elevated in mPanIN-like lesions and PDAC, in agreement with previous reports, 15, 56 and colocalized with AGR2 ( Figure 5a ). Alcian blue, a stain for mucopolysaccharides, also correlated with the sites of AGR2 expression ( Figure 5b) . Moreover, AGR2 and MUC1 colocalized in serial sections of human PanIN lesions (Figure 5c ). AGR2 also correlated occasionally with MUC5AC, but poorly with MUC4 ( Supplementary Figure S8) .
Generation of Pdx1-Cre/LSL-Kras G12D /Smad4 À / À mice with heterozygous Agr2 Because of the striking in vitro data showing that AGR2 expression was both necessary and required for MUC1 expression (Figure 4) , we sought to determine whether AGR2 was essential for MUC1 expression in vivo. Accordingly, the Agr2 knockout model 25 was crossed into Pdx1-Cre/LSL-Kras G12D /Smad4 lox/lox mice. 54 This model progresses from mPanIN-like lesions through adenocarcinoma by 5 months of age, and also develops mucinous cysts. 54 Control mice (Pdx1-Cre, LSL-Kras G12D , Smad4 lox/lox or Agr2 À / À ) exhibited normal pancreata out to 9 months of age. However, as previously shown, Agr2 À / À animals exhibited a high frequency of rectal prolapse and were often moribund by 5 months. 25 The effects of Agr2 deficiency were examined in Pdx1-Cre/LSL-Kras G12D /Smad4 lox/lox (P/K/S L/L ) animals for up to 5 months. Our final cohort consisted of 14 P/K/S L/L , 15 P/K/S L/L with one copy of Agr2 (P/K/S L/L /A þ / À ), and 3 P/K/S L/L with no copies of Agr2 (P/K/S L/L /A À / À ). Only P/K/S L/L , but not P/K/S L/L /A þ / À or P/K/S L/L / A À / À , exhibited visible tumor invasion outside the pancreas. Next, histopathological evaluation was performed on sections stained with hematoxylin and eosin or Alcian blue and immunostained for CK19 and amylase (Table 1) . Sections were evaluated for the presence of acinar-to-ductal metaplasia (ADM), mPanIN1-3, PDAC and pancreatic cysts by a pancreatic cancer pathologist (DS Longnecker) blinded to the genotype of the Early adenocarcinoma shown on the right, and is enlarged in the box. Invasive clusters surround the larger lesion and stain highly for AGR2. Magnification: Â 100; Scale bar: 40 mm. pancreatic sections. As previously reported for the P/K/S L/L model, 54 by 5 months of age the pancreata exhibited a high incidence of intraductal papillary mucinous neoplasm-like cysts (5/14), ADM (7/14), mPanIN-like lesions (10/14) and a high proportion (6/14) of 'established' PDAC, defined as lesions that contained poorly differentiated, invasive CK19-positive cancer cells. There was also a single 'early' PDAC, defined as a small lesion with finger-like loci of CK19-positive cells that were abnormal in appearance and that were in the proximity to advanced PanIN. Many of the established PDAC in these animals were large and, when measurable, averaged five mm at the widest cross-section. Of 14 P/K/S L/L animals, only 2 were histologically normal. By contrast, age-matched P/K/S L/L animals that had only one copy of Agr2 (P/K/S L/L /A þ / À ) developed a much lower incidence of ntraductal papillary mucinous neoplasm-like cysts (1/15), ADM (4/15) and mPanIN-like lesions (6/15), and the PDAC was more often an early lesion (5/15), rather than established PDAC (1/15). Only one animal had a measurable tumor (3 mm). Of the 15 total P/K/S L/L /A þ / À animals, almost half (6/15) were histologically normal. Moreover, of three P/K/S L/L /A À / À animals, only one developed a single focus of ADM with a small focus of early PDAC.
AGR2 is required for MUC1 expression in pancreatic lesions
We next sought to determine whether AGR2 and MUC1 expression was correlated in lesions formed in P/K/S L/ þ and P/K/S L/L animals that were heterozygous or null for Agr2. We used co-IF to stain the sections for AGR2/MUC1 or CK19/amylase, and stained adjacent serial sections using Alcian blue and hematoxylin and eosin. Consistent with our study of other mouse models ( Figure 5 and Supplementary Figure S7 ), lesions from animals with both alleles of Agr2 all expressed equivalently high levels of AGR2 and MUC1, and exhibited strong Alcian blue staining (Figure 6a ).
As expected, lesions that developed in P/K/S L/ þ or P/K/S L/L animals null for Agr2 lacked expression of AGR2. These lesions were also negative for MUC1 expression and Alcian blue staining (Figure 6b ). The lesions in P/K/S L/ þ or P/K/S L/L animals heterozygous for Agr2 either exhibited uniform AGR2 overexpression, a uniform lack of AGR2, or varied expression of AGR2, sometimes within the same lesion (Figures 6c and d) . In all cases, we saw parallel changes in MUC1 expression and Alcian blue staining (Figures 6c and d) .
DISCUSSION
AGR2 is a potential member of the PDI family of ER-associated enzymes that are endowed with chaperone activity and that catalyze the formation and breakage of disulfide bonds between cysteine residues of proteins, allowing for their proper folding and stable conformation. [24] [25] [26] AGR2 was previously implicated as a chaperone to MUC2 in intestinal cells, 25 and was recently shown to localize to the ER and to the cell surface of pancreatic cancer cells 38 and to be responsible for ER homeostasis. 26 AGR2 was also promotes the survival, invasion and metastasis of pancreatic cancer cells, and upregulates the expression of several ER chaperones, lysosomal proteases cathepsin B and D, and proteins implicated in the ubiquitin-proteosome degradation pathway. 38 Together, these studies underscore the important role of AGR2 in the pathobiology of PDAC.
In the present study, we found that AGR2 is abundant in the ER of pancreatic cancer cells and that its expression is induced with serum starvation. We also determined that AGR2 knockdown enhances ER stress due to the induction of an unfolded protein response, as evidenced by increased PERK and phospho-PERK levels leading to increased eIF2a phosphorylation in conjunction with increased BiP levels. Inasmuch as unfolded protein responseinduced ER stress may increase cancer chemosensitivity, these observations suggest that AGR2 downregulation may enhance the responsiveness of pancreatic cancer cells to gemcitabine through this mechanism.
Several lines of evidence indicate that TGF-b-mediated suppression of AGR2 is mediated, at least in part, by SMAD4. First, TGF-b1 reduced AGR2 levels in SMAD4-proficient cells (PANC-1 and COLO-357), but not in BxPC3 cells (homozygous deletion of SMAD4) or in ASPC-1 cells (mutated SMAD4). Second, restoring SMAD4 led to decreased AGR2 mRNA levels. Third, knockdown of SMAD4 in COLO-357 cells increased AGR2 mRNA levels. Fourth, SMAD4 and TGF-b reduced AGR2 promoter luciferase activity. Inasmuch as a mutation or deletion of SMAD4 disrupts TGF-b signaling in 55% of PDAC, 4,6,57-60 these findings suggest that loss of SMAD4, by preventing TGF-b-mediated suppression of AGR2, may constitute one mechanism whereby TGF-b converts from a tumor suppressor to a tumor promoter.
Studies using an Agr2 knockout mouse model indicated that AGR2 is required for mucin production in the intestine and that AGR2 stabilizes MUC2 (a predominant intestinal mucin) via its thioredoxin-like CXXS domain. 25 In the present study we determined that AGR2 and MUC1, but not MUC4 or MUC5AC, co-immunoprecipitated and were tightly colocalized, both in the cytoplasm and in the peri-nuclear space, suggesting that AGR2 Abbreviations: ADM, acinar-to-ductal metaplasia; Gt, genotype; P-1, mouse pancreatic intraepithelial neoplasia (mPanIN)1; P-2, mPanIN-2; P-3, mPanIN-3; PDAC, pancreatic ductal adenocarcinoma; mm tumor, widest measurement, in mm, of PDAC; PKS L/L , Pdx1-Cre/LSL-Kras G12D/ þ /Smad4 lox/lox ; PKS L/L A þ / À , Pdx1-Cre/LSL-Kras G12D/ þ /Smad4 lox/lox /Agr2 þ / À ; PKS L/L A À / À , Pdx1-Cre/LSL-Kras G12D/ þ /Smad4 lox/lox /Agr2 À / À ; X, presence of lesion designated by column heading.
AGR2 knockdown ameliorates pancreatic cancer progression AM Norris et al and MUC1 might physically interact. Using COLO-357 clones that expressed an inducible AGR2 silencing construct, we determined that suppression of AGR2 expression was associated with a progressive decrease in MUC1 protein, but not RNA levels. Moreover, engineered expression of mouse AGR2 that was not targeted by the AGR2 silencing construct restored MUC1 protein levels, thereby confirming the tight dependence of MUC1 expression on AGR2 levels. Conversely, the overexpression of AGR2 resulted in increased MUC1 protein levels. Together, these observations suggest that AGR2 increases MUC1 levels in PDAC by preventing MUC1 degradation. Alternatively, as proposed with respect to the actions of AGR2 on MUC2, 25 AGR2 may upregulate MUC1 protein by enhancing MUC1 mRNA translation. Examining pancreatic cancers arising in four different GEMMs, we determined that AGR2 expression highly overlapped with MUC1 in pancreatic lesions. This colocalization was relatively specific with respect to other MUC proteins, given that AGR2 did not colocalize with either MUC5AC or MUC4, and was also evident in human pancreatic lesions. However, AGR2 was abundant in all mPanIN-like stages in all four tested GEMMs. Although its abundance in the Pdx1-Cre/Kras G12D /Smad4 À / À mice supports our findings that AGR2 expression is SMAD4 dependent, other mechanisms must also be in play to lead to its upregulation in such diverse GEMMs. For example, it is possible that functional perturbations in TGF-b signaling lead to AGR2 upregulation. Moreover, AGR2 expression has been shown to be increased by FOXA1, FOXA2, 61 the aryl hydrocarbon receptor, 62 estrogen 63 and androgens, 64 and to be downregulated by ErbB3-binding protein 1. 61 It is likely, therefore, that there are numerous mechanisms that regulate AGR2 expression in the SMAD4-intact pancreas.
To determine whether elevated MUC1 levels could be seen in lesions devoid of AGR2 expression, we bred Agr2 knockout mice 25 into a GEMM where Smad4 deletion and Kras G12D activation is confined to the pancreas using the pancreas-specific promoter, Pdx1. 54 As homozygous Agr2 knockouts develop extra-pancreatic complications (for example, rectal prolapse 25 ) , we focused our studies on Agr2 heterozygotes. Accordingly, we bred animals with homozygous loss of Smad4 (P/K/S L/L ) and either wild-type or heterozygous expression of Agr2 and collected pancreata at regular intervals. mPanIN-like or cancer lesions that either lacked or had varied expression of AGR2 exhibited parallel changes in MUC1 expression. AGR2 entirely colocalized with MUC1 and Alcian blue. Thus, the in vivo data corroborate our conclusions based on the in vitro results that AGR2 is necessary and sufficient for MUC1 expression.
We next examined the tumor incidence of age-matched animals in our cohort. Strikingly, P/K/S L/L /A þ / À animals had significantly fewer pancreatic lesions than their wild-type Agr2 counterparts (P/K/S L/L ; Table 1 ). Thus, 40% (6/15) of the P/K/S L/L / A þ / À animals were histologically normal with no detectable pancreatic lesions, compared with only 14% (2/14) of agematched P/K/S L/L controls. This is the first study using a GEMM of PDAC to address the role of AGR2 in PDAC initiation and progression. Strikingly, mice deficient in even one allele of Agr2 exhibited a delay in PDAC initiation, or altogether failed to progress to PDAC. These observations suggest that AGR2 is a crucial component of a pathway that leads to malignant transformation downstream of oncogenic K-ras.
The mechanisms by which AGR2 contributes to PDAC initiation are not readily evident. Nonetheless, it is well established that MUC1 is directly implicated in PDAC progression, through its effects on cell-to-cell signaling, 19 induction of EMT, 65 EGFR activation 20, 21 and HER2 signaling. 22 Deletion of Muc1 in a tumor model of pancreatic cancer slowed tumor progression and resulted in a lower rate of metastasis. 66 Therefore, our observation that AGR2 is required for high levels of MUC1 protein raise the possibility that AGR2 interacts with MUC1 to promote PanIN formation and progression to PDAC. Taken together, our study delineates a previously unknown link between TGF-b and MUC1, through the candidate oncogene AGR2, and suggests that AGR2 is crucial for PanIN initiation and PDAC progression (Figure 7) . These observations raise the possibility that AGR2 is a novel molecular target for both the prevention and treatment of PDAC. For experiments with TGF-b1, cells were incubated for 24 h in serum-free medium with 500 pM TGF-b1 as previously reported. 67 For experiments with DOX, cells were grown in media containing tetracycline-free fetal bovine serum and 1-2 mM DOX. Stably infected pTRIPZ-AGR2 single-cell clones were selected using 1-2 mg/ml puromycin and stably transfected pcDNA-AGR2 cells were maintained in selective medium containing 400 mg/ ml G418. For visualization of the ER, live cells were stained with ER Tracker according to the manufacturer's protocol (Invitrogen, Carlsbad, CA, USA) after transient transfection with RFP-sham or AGR2-RFP.
MATERIALS AND METHODS

Plasmids and transduction
To generate the AGR2-luc reporter plasmid, a 2598-bp fragment of the AGR2 5 0 UTR was PCR amplified (forward: 5 0 -GGACCCATAGACACTGTGG ACC-3 0 ; reverse: 5 0 -CGGTCCAAGCTTCTGAGTG-3 0 ) from human genomic DNA (Promega, Madison, WI, USA), cloned into the pGL3 vector (Promega), and verified by sequencing. Plasmids were obtained from: SBE4-Luc TGF-b reporter (Addgene, Cambridge, MA, USA; #16495 50 ), pCMV5-DPC-HA SMAD4 (Addgene #14038 49 ), two pTRIPZ-AGR2 plasmids (Open Biosystems, Huntsville, AL, USA; V2THS_251763, V2THS_199455), pcDNA-AGR2 and AGR2-RFP (Ted R. Hupp; University of Edinburgh). Transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations or transduced by lentiviral infection.
RNA isolation and taqman analysis
RNA extracts were prepared using the Qiagen RNeasy Mini Kit and the on-column RNase-free DNase set (Qiagen, Germantown, MD, USA). cDNA was synthesized using the Superscript III First-Strand Synthesis System (Invitrogen). Quantitative PCR was performed using the Taqman gene expression primer/probe TAMRA sets and an ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). All Ct data were normalized to the 18S VIC-internal control and delta Ct values were calculated.
Immunoblotting
Cell lysates were prepared and electrophoresed as previously reported. 55 The following antibodies were used for immunoblotting: polyclonal anti-AGR2 antibody (Imgenex, San Diego, CA, USA; 1:250), monoclonal anti-AGR2 antibody (Imgenex; 1:500), monoclonal anti-MUC1 antibody (MA552MUC1-CORE; Novocastra, Buffalo Grove, IL, USA; 1:200), monoclonal anti-MUC5AC antibody (CLH2 MUC-5AC-CE; Novocastra; 1:100), monoclonal anti-MUC4 antibody (ab60720, Abcam, Cambridge MA, USA; 1:500), anti-phosphorylated or total eIF2a antibody (Cell Signaling, Danvers, MA, USA; 1:1000), anti-phosphorylated or total PERK antibody (Cell Signaling; 1:1000), anti-GRP78 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:200) or an anti-ERK2 antibody (Santa Cruz Biotechnology; 1:7000).
Luciferase assay
Reporter constructs (SBE4-Luc; AGR2-Luc) were cotransfected with CMV-Renilla using Lipofectamine 2000 (Invitrogen). Luciferase activity was determined using the Dual Luciferase Assay kit (Promega) and an LMaxII microplate reader (Molecular Devices, Sunnyvale, CA, USA). All assays were performed in triplicate, measured in duplicate and normalized to internal controls.
Immunohistochemistry/IF
Fixation, embedding, antigen retrieval and immunohistochemistry were all performed as previously reported. 55 For multiplexed IF, primary antibodies were coincubated and incubated with fluorescently conjugated secondary antibodies (Molecular Probes, Carlsbad, CA, USA). Alcian blue staining was performed as described. 68 For colocalization studies in cells, human pancreatic cells were plated in eight-well chambers on a glass slide. Cells were fixed using formalin, permeabilized using 0.05% Triton-X, and blocked with 5% BSA/1% goat serum. Cells were coincubated with the appropriate antibodies for 1 h at room temperature and then with fluorescently conjugated secondary antibodies.
Immunoprecipitation
An IP was performed using 500 mg of protein from PANC-1 cells, polyclonal anti-AGR2 antibody (Imgenex), and protein A/G agarose beads, according to the manufacturer's protocol (Santa Cruz Biotechnology). Denatured supernatant from the pull-downs was immunoblotted for mucins, as described above. For negative controls, an IgG antibody or A/G beads, alone, were used in the IP. AGR2 was immunoblotted in each experiment as a positive control.
Image capture and analysis
All images were taken using an Olympus BX60 microscope (Olympus, Center Valley, PA, USA) equipped with an Olympus DP70 camera and ImagePro software (Media Cybernetics, Rockville, MD, USA). For fluorescent images, individual monochrome pictures were captured for each channel and then merged using Adobe Photoshop CS3 software (version 10.0.1). Live cells were imaged using the Confocal Microscopy Core at Dartmouth Medical School.
Mouse husbandry
Breeding was initiated with the following: LSL-Kras G12D mice (01XJ6-B6.129-Kras2 tm4Tyj , Mouse Models of Human Cancers Consortium, National Cancer Institute, Frederick, MD 52 ), Pdx1-Cre mice (G Gu 69 ), Smad4 lox/lox mice (N Bardeesy 54 ) and Agr2 À / À mice (D Erle 25 ). Founder strains were bred to generate Pdx1-Cre/LSL-Kras G12D /Smad4 lox/lox as previously described 54 with or without loss of Agr2. All studies with mice were approved by the Dartmouth Medical School and Indiana University School of Medicine Institutional Animal Care and Use Committees. Figure 7 . Model of AGR2 regulation by TGF-b and its involvement with MUC1 in pancreatic cancer cells. We describe a model in which, through one of potentially many mechanisms, AGR2 is negatively regulated by TGF-b signaling. In the presence of TGF-b, SMAD4 translocates to the nucleus, binds to SMAD-binding elements and interacts with nuclear effectors of transcription. In the case of AGR2, SMAD4 facilitates a repression of AGR2 transcription and prevents its downstream stabilization of MUC1 in the endoplasmic reticulum.
